Novartis receives positive CHMP opinion for Ilaris®
26 July 2013 | By Novartis
Novartis announced that the CHMP of the EMA has adopted a positive opinion for the use of Ilaris® (canakinumab)...
List view / Grid view
26 July 2013 | By Novartis
Novartis announced that the CHMP of the EMA has adopted a positive opinion for the use of Ilaris® (canakinumab)...
26 July 2013 | By Novartis
Novartis announced that the EMA's CHMP has adopted a positive opinion for approval of once-daily Ultibro® Breezhaler®...
24 July 2013 | By Novartis
Following JCVI interim recommendation on Novartis Bexsero® vaccine...
17 July 2013 | By Novartis
The Novartis Board of Directors announced a final agreement with its former Chairman, Dr. Daniel Vasella.
8 July 2013 | By Novartis
All primary & secondary endpoints were met...
8 July 2013 | By Novartis
Novartis has entered into a development and licensing agreement with Biological E Limited...
26 June 2013 | By Novartis
Novartis announced late-breaking results...
24 June 2013 | By Novartis
Sandoz has initiated a major Phase III clinical trial with its biosimilar version of etanercept (Amgen's Enbrel®)...
21 June 2013 | By Novartis
RLX030 has the potential to address a serious unmet medical need...
17 June 2013 | By Novartis
The Novartis Prizes for Immunology are awarded to three scientists...
16 June 2013 | By Novartis
Results from a Phase III three-year follow-up study...
10 June 2013 | By Novartis
Two new analyses from the Phase III TRANSFORMS study presented...
5 June 2013 | By Novartis
Gilenya improved the key measures...
3 June 2013 | By Novartis
Novartis announced data on its investigational compound LDK378...
2 June 2013 | By Novartis
Results from a pivotal Phase III trial...